CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation

NCT ID: NCT06959121

Last Updated: 2026-01-12

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 135 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-10-23
• Study Completion Date: 2028-12-31

Brief Summary

The primary objective of this Pivotal study is to demonstrate the safety and effectiveness of the Pulse Biosciences nsPFA™ Cardiac Surgery System in treating atrial fibrillation during concomitant cardiac surgical procedures.

Detailed Description

The study design is a prospective, multicenter, non-randomized single arm study. Eligible adult subjects with paroxysmal or persistent/longstanding persistent AF who are eligible to participate will undergo a concomitant cardiac surgical procedure with CellFX nsPFA Cardiac Surgery System ablation and left atrial appendage exclusion or removal. The left atrial wall isolation will include left and right pulmonary vein isolation as well as isolation of the left atrial posterior wall through left atrial roof and floor lesions. The left atrial posterior wall isolation (PWI) can be formed by either allowing a closed LA epicardial only lesion encompassing the entire posterior wall of the left atrium or by a combined epicardial/endocardial approach when the left atrium is open.

Primary effectiveness endpoint is freedom from any AF/AFL/AT lasting > 30 seconds and freedom for use of new or increased dose of previously failed Class I or III antiarrhythmic drugs (AADs) prescribed to treat atrial arrhythmias following the 90-day blanking period through 6 months post the concomitant surgical and ablation procedure by a core lab.

Primary safety endpoint is the incidence of acute major adverse events (MAEs), which includes death, stroke, myocardial infarction (MI), transient ischemic attack (TIA), or excessive bleeding (Bleeding Academic Research Consortium (BARC) 3b, 4, or 5) within 30 days post-concomitant surgical procedure. These events may be related to either the cardiac surgical procedure or the ablation procedure. All MAE events will be reviewed and adjudicated by an independent Clinical Events Committee (CEC).

Conditions

Atrial Fibrillation; Maze Procedure; AF; Ablation

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

CellFX nsPFA Clamp

Adult subjects who are eligible to participate will undergo a concomitant cardiac surgical procedure with nsPFA ablation (of left and right pulmonary veins as well as roof and floor lesions to form a box) and treatment of left atrial appendage.

Group Type: EXPERIMENTAL

CellFX® nsPFA™ Cardiac Surgery System

Intervention Type: DEVICE

Participants will receive cardiac ablation with the CellFX® nsPFA™ Cardiac Clamp

Interventions

CellFX® nsPFA™ Cardiac Surgery System

Participants will receive cardiac ablation with the CellFX® nsPFA™ Cardiac Clamp

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Subject must be between 18 and 85 years of age
• Subject is willing and capable of providing Informed Consent to undergo study procedures which include the potential for surgical AF ablation, and completion of follow-up visits as specified in the clinical study protocol
• Subject has history of documented paroxysmal atrial fibrillation (AF that is intermittent and terminates within ≤ 7 days of onset) or persistent/longstanding persistent atrial fibrillation (AF that is continuous and sustains for > 7 days and requires intervention) within one year prior to enrollment. Documentation may include ECG, transtelephonic monitor (TTM), Holter monitor or telemetry strip from the study hospital or an outside physician
• Subject is scheduled to undergo non-emergent cardiac surgical procedure(s) to be performed on cardiopulmonary bypass including open-heart surgery via sternotomy for one or more of the following: Mitral valve repair or replacement, Aortic valve repair or replacement, Ascending aortic aneurysms, Atrial Septal Defect (ASD)/Patent Foramen Ovale (PFO) or Coronary artery bypass procedures
• Left ventricular ejection fraction ≥ 30% (determined by echocardiography or cardiac catheterization performed within 60 days of enrollment as documented in patient medical history)
• Subject has a life expectancy of at least 5 years
• Subject currently lives within a reasonable commuting distance of the investigational site and plans to remain geographically stable through 12 month follow up

Exclusion Criteria

• Subject has an implantable electronic medical device. (i.e., pacemaker, implantable cardioverter-defibrillator (ICD), or Cardiac Resynchronization Therapy (CRT) or left atrial appendage (LAA) device
• Subject has history or known to have LAA clot
• Subject has a prosthetic heart valve
• Stand- alone AF without indication(s) for concomitant Coronary Artery Bypass Graft (CABG) and/or valve surgery
• Prior cardiac surgery including prior cardiac surgical ablation
• Left Atrial diameter ≥ 6cm
• Wolff-Parkinson-White syndrome or other Supra-Ventricular Arrhythmia, Atrioventricular (AV) nodal reentry
• Documented history of persistent or long standing persistent atrial fibrillation longer than 10 years
• Subjects requiring surgery other than CABG and/or cardiac valve surgery and/or atrial septal defect repair/PFO and ascending aorta
• Prior history of medical procedure involving instrumentation of the left atrium (e.g., previous ablation)
• Subjects that are on an AAD for ventricular arrhythmia.
• STS Predicted Risk of Mortality (STS PROM) of 10 or higher
• Class III or IV New York Heart Association (NYHA) heart failure symptoms
• Prior history of stroke within 6 months
• Documented ST-segment elevation Myocardial Infarction (MI) within the 6 weeks prior to study enrollment
• Need for emergent cardiac surgery (per sit-to-stand (STS) test definition)
• Known carotid artery stenosis greater than 80%
• Current diagnosis of active systemic infection
• Severe peripheral arterial occlusive disease defined as claudication with minimal exertion
• Renal failure requiring dialysis or hepatic failure (significant liver dysfunction with markedly significant elevation of liver enzymes, such as cirrhosis with decompensation, portal hypertension, or a history of hepatic failure)
• A known drug and/or alcohol addiction
• Mental impairment or other conditions that may not allow the subject to understand the nature, significance, and scope of the study
• Pregnancy or desire to get pregnant within 12 months of the study treatment
• Preoperative need for an intra-aortic balloon pump or intravenous inotropes
• Subjects who have been treated with thoracic radiation
• Subjects in current chemotherapy
• Subjects on long-term treatment with oral or injected steroids (not including intermittent use of inhaled steroids for respiratory diseases)
• Subjects with known hypertrophic obstructive cardiomyopathy
• Subjects with known cold agglutinin
• Subject has a contraindication to anticoagulation (e.g., a bleeding or clotting disorder such as Idiopathic Thrombocytopenic Purpura (ITP))
• Solid organ or hematologic transplant, or currently being evaluated for an organ transplant
• Body mass index > 45 kg/m2
• Any diagnosed connective tissue disorder
• Severe Chronic Obstructive Pulmonary Disease (COPD) per sit-to-stand (STS) test definition
• Use of any other investigational drug, therapy, or device within 30 days before enrollment or concurrent participation in another research study

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Avania

INDUSTRY

Sponsor Role: collaborator

Pulse Biosciences, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Matthew A. Romano, MD

Role: PRINCIPAL_INVESTIGATOR

University of Michigan, Cardiac Surgery Clinic | Frankel Cardiovascular Center

Locations

Adventist Heart Institute: Adventist Health St. Helena

St. Helena, California, United States

Site Status: RECRUITING

Cardiac Surgery Clinic | Frankel Cardiovascular Center

Ann Arbor, Michigan, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Shweta Kalpa, MD

Role: CONTACT

Shweta.Kalpa@pulsebiosciences.com

(800) 543-3695

William A. Knape

Role: CONTACT

bknape@pulsebiosciences.com

(919) 757-2033

Facility Contacts

Aaron M Kime, MD

Role: primary

707-963-7200

Matthew A Romano, MD

Role: primary

888-287-1082

Other Identifiers

NP-PCP-041

Identifier Type: -

Identifier Source: org_study_id